Our project endeavors to assess the feasibility of utilizing siRNA to inhibit EIF6, subsequently impeding cancer cell glycolysis, and enhancing the responsiveness of apatinib in the treatment of glioblastoma. We have undertaken an extensive exploration, mathematical modeling, and expert consultation to navigate the complexities of this challenging endeavor. Throughout the course of our project, we engaged with a multidisciplinary team of experts including oncologists specializing in glioblastoma, molecular biologists, and pharmaceutical experts. Their collective wisdom and guidance were instrumental in shaping our approach, addressing unforeseen challenges, and ensuring the safety and effectiveness of our proposed treatment.

Furthermore, our human practices component of the project played a pivotal role in refining our strategy. We recognized the pressing issue of accessibility in healthcare, particularly in the context of glioblastoma treatment. While some individuals have access to cutting-edge therapies at prestigious medical centers, the majority face disparities in healthcare. This is especially critical in the backdrop of the glioblastoma pandemic, where the need for universally accessible treatments has never been more urgent.

In alignment with our commitment to accessibility, we conducted extensive research and surveys to gain insights into the real-world challenges faced by glioblastoma patients. We analyzed data from diverse sources, including medical literature, clinical trials, and patient interviews. This comprehensive approach allowed us to tailor our project to meet the specific needs and limitations of glioblastoma patients. In conclusion, our project is a testament to the potential of siRNA inhibition of EIF6 as a novel approach in glioblastoma treatment. By collaborating with experts and addressing the critical issue of accessibility, we aim to make strides towards more equitable and effective treatments for this devastating disease.

Dr. Furan Song, an expert in drug delivery vehicles, played a pivotal role in guiding our research endeavors. Before our consultation with Dr. Song, we were exploring the potential use of siRNA as a therapeutic tool for drug delivery. Dr. Song provided a comprehensive overview of the research landscape surrounding siRNA drug delivery, affirming the promise of our approach. He emphasized the importance of ensuring the stability and durability of siRNA molecules in drug delivery systems, offering valuable insights into addressing these challenges.

Furthermore, Dr. Song encouraged us to diversify our target selection and explore the rationality of EIF6 as a potential target. His expertise illuminated the intricate dynamics involved in siRNA-based therapies, fostering a more comprehensive understanding of our research scope.

In addition to scientific guidance, Dr. Song underscored the significance of considering societal acceptance and the associated high costs of siRNA-based drugs. This holistic perspective is invaluable as we strive to bridge the gap between cutting-edge research and practical, accessible healthcare solutions.

Figure 1. Interviewing Dr.Song

Associate Professor Yu-Dong Miao provided vital perspectives on our project. He emphasized that our national medical insurance, especially in Henan Province, has already included effective cancer treatments, easing the financial burden on patients. However, he noted the slow progress and high cost of siRNA-based therapies, which can reach ¥120,000 RMB (around $18,750 USD) per injection.

Dr. Miao highlighted the importance of conducting further clinical trials to assess potential side effects and gradually expanding the market to reduce drug costs. The ultimate goal is to integrate siRNA therapies into the basic medical security system, ensuring widespread access.

Patient awareness of siRNA treatments is currently low, so Dr. Miao stressed the need for patient education and promoting knowledge about targeted therapies. He also recommended exploring complementary treatments like traditional Chinese medicine and massage to improve patient quality of life and extend survival, helping to alleviate the psychological stress associated with cancer.

Figure 3. Interviewing Professor Miao

WWe had the privilege of interviewing Dr. Hongqi Li, the Director of Oncology, in his office. Dr. Li expressed his view on the current trends in cancer treatment research, particularly focusing on miRNA and siRNA as promising avenues for targeted therapies. He emphasized that inhibiting glycolysis through EIF6 to enhance the sensitivity of Apatinib holds substantial research value.

Considering the time constraints of our iGEM project, our research primarily delves into the cellular aspects of this endeavor. As a medical professional, Dr. Li places a significant emphasis on the cost and safety of targeted therapeutic drugs. He believes that finding safe and effective ways to enhance the performance of existing chemotherapy drugs holds great clinical promise.

However, Dr. Li also underscored the importance of addressing potential adverse reactions that may arise from the combination of siRNA and chemotherapy drugs. Patients' quality of life often takes a toll due to issues like poor appetite, nausea, headaches, and psychological stress, all of which can lead to sleep disturbances. Dr. Li suggested that our iGEM team explore solutions to improve the quality and duration of sleep for glioblastoma patients, possibly by developing devices tailored to their needs.

Figure 4. Interviewing Dr.Li

Our iGEM team places great value on the insights and recommendations provided by experts in various fields. The feedback and guidance we received have significantly influenced our project in three key areas.

Smart Sleep Helmet Development for Improved Sleep Quality

One major concern highlighted by experts, particularly Dr. Hongqi Li, the Director of Oncology, was the issue of sleep quality in glioblastoma patients. Recognizing the importance of addressing this challenge, we have incorporated the development of an intelligent sleep helmet into our project. This innovative device aims to enhance the quality of sleep for patients by mitigating common issues such as poor appetite, nausea, headaches, and psychological stress, which are often associated with cancer and its treatment. By integrating this solution, we aim to provide a holistic approach to improving the well-being and life quality of patients undergoing cancer therapy.

Figure 5. Adjusting the Functions of the Smart Sleep Aid Helmet

Selection of EIF6 as the Target for siRNA

Dr. Weitian Long, an expert in drug delivery systems, pointed out the significance of selecting an appropriate target for our siRNA-based therapy. After conducting extensive literature research and analysis, we chose EIF6 as our target. This decision was made based on robust scientific evidence, highlighting EIF6's relevance in glioblastoma. The selection process involved a thorough examination of its specificity and minimal off-target effects, thus ensuring the safety and precision of our approach.

Figure 6. EIF6

Rigorous Design and Focus on In-Vitro Studies:

As per the advice from multiple experts, including Dr. Weitian Long and Dr. Hongqi Li, we have meticulously designed our project to emphasize in-vitro studies. This approach not only allows us to investigate the molecular mechanisms involved in EIF6 inhibition but also minimizes potential adverse reactions associated with siRNA therapies. By concentrating on cell-based experiments and avoiding clinical components within the scope of our iGEM project, we prioritize the safety and reliability of our research while laying a robust foundation for future translational work.

Figure 7. cell invasion of cells